We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CALID Arm Growth to Support Bruker Shares Amid Macro Issues
Read MoreHide Full Article
Bruker’s (BRKR - Free Report) strong growth reflects its fundamental commitment to innovate high-value solutions and its ongoing portfolio transformation. Yet, the company’s operations face the wrath of excessive currency exposure and general macroeconomic headwinds. The stock carries a Zacks Rank #3 (Hold).
Factors Driving Bruker's Growth
The CALID segment has been gaining from strong demand for differentiated instruments, particularly in life science mass spectrometry proteomics solutions and optics spectroscopy and microscopy instruments. In 2024, the company unveiled the flagship timsTOF Ultra 2, featuring significantly enhanced sensitivity for single-cell proteomics and immunopeptidomics. It offers new possibilities in subcellular proteomics. Bruker also introduced the neofleX MALDI-TOF/TOF multiomic Mass Spec Imaging Benchtop system, which is set to enable multiomic colocalization on the tissue of proteins, lipids, metabolites and glycosylation.
Earlier this year, Bruker augmented its molecular microscopy portfolio by acquiring Nanophoton, adding a broad range of state-of-the-art Raman microscopy systems. Furthermore, the acquisition of Tornado Spectral Systems in January aims to significantly expand Bruker’s biopharma PAT (Process Analytical Technology) product portfolio range.
Within the BSI Nano segment, Bruker has enhanced its materials science research portfolio with the acquisition of Nion by adding a high-end STEM (scanning transmission electron microscope) technology. It also completed the acquisition of Phasefocus Holdings Limited, the developer of a novel optical microscope called Livecyte for label-free imaging. In May 2024, the company purchased NanoString Technologies’ assets, bringing innovative platforms and solutions for spatial transcriptomics and gene expression analysis into the NANO segment.
Further, Bruker is strategically progressing with its BioSpin products that have specific applications in structural proteomics, drug discovery, research, and food and materials science fields, providing customers with the ability to ascertain the structure, dynamics, and function of specific molecules, such as proteins, as well as characterize and determine the composition of mixtures. The company’s SciY platform, which offers a comprehensive, vendor-agnostic suite of software and automation solutions for life science industry customers, primarily in the biopharma sector, has been seeing greater adoption. In addition, the division also benefits from enabling access to its high-performance GHz (gigahertz) NMR (Nuclear Magnetic Resonance) technology.
Present global economic challenges and uncertainties have made it harder for Bruker to manage operations and predict financial outcomes. Geopolitical conditions, including conflicts in Russia and Ukraine, Israel, Palestine and surrounding areas, tensions between the United States and China, potential energy shortages in Europe and increased energy and transportation costs are impacting the company’s operational results. In addition, supply-chain risks associated with inflation, the threat of recession, currency volatility, and the worldwide shortage of semiconductor chips, components and raw materials such as copper also persist. All these issues are leading to higher costs and expenditures for the company and putting pressure on profitability.
In the third quarter, Bruker’s cost of revenues increased by 23.8% compared with the same period in 2023. Selling, general and administrative (SG&A) expenses surged 30.2%.
Bruker generates a substantial portion of its revenues from international markets, primarily in Germany and other countries in the European Union, Switzerland and Japan. As a result, currency fluctuations continue to result in foreign currency transaction losses at the company. In addition, currency fluctuations could cause the price of Bruker’s products to be less competitive than its principal competitors' offerings.
Moreover, Bruker faces substantial competition in a consolidating industry and expects competition in all its markets to increase further. Bruker BioSpin competes with companies that offer magnetic resonance spectrometers, mainly JEOL and Oxford Instruments. In the field of preclinical imaging, Bruker BioSpin faces competitive threats from Perkin Elmer, Mediso, Trifoil, MR Solutions, RS2D, Visualsonics (Fuji Film) and others.
The stock has lost 9.4% in the past six months compared with the industry’s 8.4% fall. With the company currently focusing on core business expansion through innovations, new offerings and expansion into new markets, we expect the stock to regain momentum in the coming days.
Phibro Animal Health’s shares have risen 86.2% in the past year. Estimates for the company’s fiscal 2025 earnings per share have remained constant at $1.62 in the past 30 days. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.47%. In the last reported quarter, it posted an earnings surprise of 52.17%.
Estimates for Penumbra’s 2024 earnings per share have remained constant at $2.81 in the past 30 days. Shares of the company have risen 4.3% in the past year compared with the industry’s 7.2% rise. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 10.54%. In the last reported quarter, it delivered an earnings surprise of 23.19%.
Estimates for Haemonetics’ fiscal 2025 earnings per share have remained constant at $4.59 in the past 30 days. Shares of the company have declined 5.9% in the past year against the industry’s growth of 4.7%. HAE’s earnings surpassed estimates in three of the trailing four quarters and matched in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
CALID Arm Growth to Support Bruker Shares Amid Macro Issues
Bruker’s (BRKR - Free Report) strong growth reflects its fundamental commitment to innovate high-value solutions and its ongoing portfolio transformation. Yet, the company’s operations face the wrath of excessive currency exposure and general macroeconomic headwinds. The stock carries a Zacks Rank #3 (Hold).
Factors Driving Bruker's Growth
The CALID segment has been gaining from strong demand for differentiated instruments, particularly in life science mass spectrometry proteomics solutions and optics spectroscopy and microscopy instruments. In 2024, the company unveiled the flagship timsTOF Ultra 2, featuring significantly enhanced sensitivity for single-cell proteomics and immunopeptidomics. It offers new possibilities in subcellular proteomics. Bruker also introduced the neofleX MALDI-TOF/TOF multiomic Mass Spec Imaging Benchtop system, which is set to enable multiomic colocalization on the tissue of proteins, lipids, metabolites and glycosylation.
Earlier this year, Bruker augmented its molecular microscopy portfolio by acquiring Nanophoton, adding a broad range of state-of-the-art Raman microscopy systems. Furthermore, the acquisition of Tornado Spectral Systems in January aims to significantly expand Bruker’s biopharma PAT (Process Analytical Technology) product portfolio range.
Within the BSI Nano segment, Bruker has enhanced its materials science research portfolio with the acquisition of Nion by adding a high-end STEM (scanning transmission electron microscope) technology. It also completed the acquisition of Phasefocus Holdings Limited, the developer of a novel optical microscope called Livecyte for label-free imaging. In May 2024, the company purchased NanoString Technologies’ assets, bringing innovative platforms and solutions for spatial transcriptomics and gene expression analysis into the NANO segment.
Further, Bruker is strategically progressing with its BioSpin products that have specific applications in structural proteomics, drug discovery, research, and food and materials science fields, providing customers with the ability to ascertain the structure, dynamics, and function of specific molecules, such as proteins, as well as characterize and determine the composition of mixtures. The company’s SciY platform, which offers a comprehensive, vendor-agnostic suite of software and automation solutions for life science industry customers, primarily in the biopharma sector, has been seeing greater adoption. In addition, the division also benefits from enabling access to its high-performance GHz (gigahertz) NMR (Nuclear Magnetic Resonance) technology.
Bruker Corporation Price
Bruker Corporation price | Bruker Corporation Quote
Concerning Factors for BRKR
Present global economic challenges and uncertainties have made it harder for Bruker to manage operations and predict financial outcomes. Geopolitical conditions, including conflicts in Russia and Ukraine, Israel, Palestine and surrounding areas, tensions between the United States and China, potential energy shortages in Europe and increased energy and transportation costs are impacting the company’s operational results. In addition, supply-chain risks associated with inflation, the threat of recession, currency volatility, and the worldwide shortage of semiconductor chips, components and raw materials such as copper also persist. All these issues are leading to higher costs and expenditures for the company and putting pressure on profitability.
In the third quarter, Bruker’s cost of revenues increased by 23.8% compared with the same period in 2023. Selling, general and administrative (SG&A) expenses surged 30.2%.
Bruker generates a substantial portion of its revenues from international markets, primarily in Germany and other countries in the European Union, Switzerland and Japan. As a result, currency fluctuations continue to result in foreign currency transaction losses at the company. In addition, currency fluctuations could cause the price of Bruker’s products to be less competitive than its principal competitors' offerings.
Moreover, Bruker faces substantial competition in a consolidating industry and expects competition in all its markets to increase further. Bruker BioSpin competes with companies that offer magnetic resonance spectrometers, mainly JEOL and Oxford Instruments. In the field of preclinical imaging, Bruker BioSpin faces competitive threats from Perkin Elmer, Mediso, Trifoil, MR Solutions, RS2D, Visualsonics (Fuji Film) and others.
The stock has lost 9.4% in the past six months compared with the industry’s 8.4% fall. With the company currently focusing on core business expansion through innovations, new offerings and expansion into new markets, we expect the stock to regain momentum in the coming days.
Key Picks
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Penumbra (PEN - Free Report) and Haemonetics (HAE - Free Report) . While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Penumbra and Haemonetics carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Phibro Animal Health’s shares have risen 86.2% in the past year. Estimates for the company’s fiscal 2025 earnings per share have remained constant at $1.62 in the past 30 days. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.47%. In the last reported quarter, it posted an earnings surprise of 52.17%.
Estimates for Penumbra’s 2024 earnings per share have remained constant at $2.81 in the past 30 days. Shares of the company have risen 4.3% in the past year compared with the industry’s 7.2% rise. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 10.54%. In the last reported quarter, it delivered an earnings surprise of 23.19%.
Estimates for Haemonetics’ fiscal 2025 earnings per share have remained constant at $4.59 in the past 30 days. Shares of the company have declined 5.9% in the past year against the industry’s growth of 4.7%. HAE’s earnings surpassed estimates in three of the trailing four quarters and matched in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.